Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

OBJECTIVE:This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC. SUMMARY BACKGROUND DATA:To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of surgery 2022-08, Vol.276 (2), p.298-304
Hauptverfasser: Matsuda, Satoru, Kawakubo, Hirofumi, Okamura, Akihiko, Takahashi, Keita, Toihata, Tasuku, Takemura, Ryo, Mayanagi, Shuhei, Hirata, Kenro, Irino, Tomoyuki, Hamamoto, Yasuo, Takeuchi, Hiroya, Watanabe, Masayuki, Kitagawa, Yuko
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 304
container_issue 2
container_start_page 298
container_title Annals of surgery
container_volume 276
creator Matsuda, Satoru
Kawakubo, Hirofumi
Okamura, Akihiko
Takahashi, Keita
Toihata, Tasuku
Takemura, Ryo
Mayanagi, Shuhei
Hirata, Kenro
Irino, Tomoyuki
Hamamoto, Yasuo
Takeuchi, Hiroya
Watanabe, Masayuki
Kitagawa, Yuko
description OBJECTIVE:This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC. SUMMARY BACKGROUND DATA:To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who responded to NAC, the distribution of residual disease needs to be elucidated. Given that the residual tumor is located in the regional field, chemoradiotherapy can be safely added to eliminate the residual disease. METHODS:Overall, 483 patients with resectable ESCC who received NAC followed by transthoracic esophagectomy at 2 high-volume centers were reviewed. The recurrence-free survival, overall survival (OS), and residual and recurrent tumor patterns were compared among the pathological responses. RESULTS:Compared with nonpathological responders, pathological responders exhibited significantly longer recurrence-free survival [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.25 (P < 0.001) /0.17 (P < 0.001) /0.16 (P = 0.003)] and OS [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.26 (P < 0.001) /0.12 (P < 0.001) /0.11 (P = 0.003)]. In terms of the distribution of recurrence, the percentages of solitary recurrence in the regional field out of all recurrence was significantly higher in patients with Grade 1b (60%) / 2 (67%) / 3 (67%) whereas less than 25% in Grade 0 or 1a. CONCLUSIONS:It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.
doi_str_mv 10.1097/SLA.0000000000004436
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2452498126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2452498126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3996-ed028be6160ece4ee84d47e69dedc7132b9cfa89a28898fd363c70ea9c45dadd3</originalsourceid><addsrcrecordid>eNp9kbFu2zAQhokiAeq6eYMOHLMoJSVaIkdDcdMARls0ySycyVPEVCJlUoqRR-nbloYzBB3ChcTP_zvc3U_IF86uOFPV17vt-oq9OUIU5Qey4KtcZpwLdkYWSS0yoYr8I_kU4xNjXEhWLcjfaxunYHfzZL2jvqW_MVozQ0_TB0JECs4kUc8hoNNIf8E0YXCRWnd8d773j1YnfwJH7wyGSNdtstAf6ME8zc_gJlp3OPipwwDjC219oJvoxw4eMYF3-xkGP0daY9_TGoK2zg_wmZy30Ee8eL2X5OHb5r7-nm1_3tzW622mC6XKDA3L5Q5LXjLUKBClMKLCUhk0uuJFvlO6Bakgl1LJ1hRloSuGoLRYGTCmWJLLU90x-P2McWoGG3VqBRymrppcrHKhJM_LZBUnqw4-xoBtMwY7QHhpOGuOSTQpieb_JBImT9jB92kx8U8_HzA0XRp-6t5H_wFW1JE2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452498126</pqid></control><display><type>article</type><title>Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma</title><source>PubMed Central</source><source>Journals@Ovid Complete</source><creator>Matsuda, Satoru ; Kawakubo, Hirofumi ; Okamura, Akihiko ; Takahashi, Keita ; Toihata, Tasuku ; Takemura, Ryo ; Mayanagi, Shuhei ; Hirata, Kenro ; Irino, Tomoyuki ; Hamamoto, Yasuo ; Takeuchi, Hiroya ; Watanabe, Masayuki ; Kitagawa, Yuko</creator><creatorcontrib>Matsuda, Satoru ; Kawakubo, Hirofumi ; Okamura, Akihiko ; Takahashi, Keita ; Toihata, Tasuku ; Takemura, Ryo ; Mayanagi, Shuhei ; Hirata, Kenro ; Irino, Tomoyuki ; Hamamoto, Yasuo ; Takeuchi, Hiroya ; Watanabe, Masayuki ; Kitagawa, Yuko</creatorcontrib><description>OBJECTIVE:This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC. SUMMARY BACKGROUND DATA:To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who responded to NAC, the distribution of residual disease needs to be elucidated. Given that the residual tumor is located in the regional field, chemoradiotherapy can be safely added to eliminate the residual disease. METHODS:Overall, 483 patients with resectable ESCC who received NAC followed by transthoracic esophagectomy at 2 high-volume centers were reviewed. The recurrence-free survival, overall survival (OS), and residual and recurrent tumor patterns were compared among the pathological responses. RESULTS:Compared with nonpathological responders, pathological responders exhibited significantly longer recurrence-free survival [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.25 (P &lt; 0.001) /0.17 (P &lt; 0.001) /0.16 (P = 0.003)] and OS [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.26 (P &lt; 0.001) /0.12 (P &lt; 0.001) /0.11 (P = 0.003)]. In terms of the distribution of recurrence, the percentages of solitary recurrence in the regional field out of all recurrence was significantly higher in patients with Grade 1b (60%) / 2 (67%) / 3 (67%) whereas less than 25% in Grade 0 or 1a. CONCLUSIONS:It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.</description><identifier>ISSN: 0003-4932</identifier><identifier>EISSN: 1528-1140</identifier><identifier>DOI: 10.1097/SLA.0000000000004436</identifier><language>eng</language><publisher>Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><ispartof>Annals of surgery, 2022-08, Vol.276 (2), p.298-304</ispartof><rights>Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3996-ed028be6160ece4ee84d47e69dedc7132b9cfa89a28898fd363c70ea9c45dadd3</citedby><cites>FETCH-LOGICAL-c3996-ed028be6160ece4ee84d47e69dedc7132b9cfa89a28898fd363c70ea9c45dadd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Matsuda, Satoru</creatorcontrib><creatorcontrib>Kawakubo, Hirofumi</creatorcontrib><creatorcontrib>Okamura, Akihiko</creatorcontrib><creatorcontrib>Takahashi, Keita</creatorcontrib><creatorcontrib>Toihata, Tasuku</creatorcontrib><creatorcontrib>Takemura, Ryo</creatorcontrib><creatorcontrib>Mayanagi, Shuhei</creatorcontrib><creatorcontrib>Hirata, Kenro</creatorcontrib><creatorcontrib>Irino, Tomoyuki</creatorcontrib><creatorcontrib>Hamamoto, Yasuo</creatorcontrib><creatorcontrib>Takeuchi, Hiroya</creatorcontrib><creatorcontrib>Watanabe, Masayuki</creatorcontrib><creatorcontrib>Kitagawa, Yuko</creatorcontrib><title>Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma</title><title>Annals of surgery</title><description>OBJECTIVE:This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC. SUMMARY BACKGROUND DATA:To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who responded to NAC, the distribution of residual disease needs to be elucidated. Given that the residual tumor is located in the regional field, chemoradiotherapy can be safely added to eliminate the residual disease. METHODS:Overall, 483 patients with resectable ESCC who received NAC followed by transthoracic esophagectomy at 2 high-volume centers were reviewed. The recurrence-free survival, overall survival (OS), and residual and recurrent tumor patterns were compared among the pathological responses. RESULTS:Compared with nonpathological responders, pathological responders exhibited significantly longer recurrence-free survival [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.25 (P &lt; 0.001) /0.17 (P &lt; 0.001) /0.16 (P = 0.003)] and OS [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.26 (P &lt; 0.001) /0.12 (P &lt; 0.001) /0.11 (P = 0.003)]. In terms of the distribution of recurrence, the percentages of solitary recurrence in the regional field out of all recurrence was significantly higher in patients with Grade 1b (60%) / 2 (67%) / 3 (67%) whereas less than 25% in Grade 0 or 1a. CONCLUSIONS:It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.</description><issn>0003-4932</issn><issn>1528-1140</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kbFu2zAQhokiAeq6eYMOHLMoJSVaIkdDcdMARls0ySycyVPEVCJlUoqRR-nbloYzBB3ChcTP_zvc3U_IF86uOFPV17vt-oq9OUIU5Qey4KtcZpwLdkYWSS0yoYr8I_kU4xNjXEhWLcjfaxunYHfzZL2jvqW_MVozQ0_TB0JECs4kUc8hoNNIf8E0YXCRWnd8d773j1YnfwJH7wyGSNdtstAf6ME8zc_gJlp3OPipwwDjC219oJvoxw4eMYF3-xkGP0daY9_TGoK2zg_wmZy30Ee8eL2X5OHb5r7-nm1_3tzW622mC6XKDA3L5Q5LXjLUKBClMKLCUhk0uuJFvlO6Bakgl1LJ1hRloSuGoLRYGTCmWJLLU90x-P2McWoGG3VqBRymrppcrHKhJM_LZBUnqw4-xoBtMwY7QHhpOGuOSTQpieb_JBImT9jB92kx8U8_HzA0XRp-6t5H_wFW1JE2</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Matsuda, Satoru</creator><creator>Kawakubo, Hirofumi</creator><creator>Okamura, Akihiko</creator><creator>Takahashi, Keita</creator><creator>Toihata, Tasuku</creator><creator>Takemura, Ryo</creator><creator>Mayanagi, Shuhei</creator><creator>Hirata, Kenro</creator><creator>Irino, Tomoyuki</creator><creator>Hamamoto, Yasuo</creator><creator>Takeuchi, Hiroya</creator><creator>Watanabe, Masayuki</creator><creator>Kitagawa, Yuko</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220801</creationdate><title>Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma</title><author>Matsuda, Satoru ; Kawakubo, Hirofumi ; Okamura, Akihiko ; Takahashi, Keita ; Toihata, Tasuku ; Takemura, Ryo ; Mayanagi, Shuhei ; Hirata, Kenro ; Irino, Tomoyuki ; Hamamoto, Yasuo ; Takeuchi, Hiroya ; Watanabe, Masayuki ; Kitagawa, Yuko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3996-ed028be6160ece4ee84d47e69dedc7132b9cfa89a28898fd363c70ea9c45dadd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsuda, Satoru</creatorcontrib><creatorcontrib>Kawakubo, Hirofumi</creatorcontrib><creatorcontrib>Okamura, Akihiko</creatorcontrib><creatorcontrib>Takahashi, Keita</creatorcontrib><creatorcontrib>Toihata, Tasuku</creatorcontrib><creatorcontrib>Takemura, Ryo</creatorcontrib><creatorcontrib>Mayanagi, Shuhei</creatorcontrib><creatorcontrib>Hirata, Kenro</creatorcontrib><creatorcontrib>Irino, Tomoyuki</creatorcontrib><creatorcontrib>Hamamoto, Yasuo</creatorcontrib><creatorcontrib>Takeuchi, Hiroya</creatorcontrib><creatorcontrib>Watanabe, Masayuki</creatorcontrib><creatorcontrib>Kitagawa, Yuko</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsuda, Satoru</au><au>Kawakubo, Hirofumi</au><au>Okamura, Akihiko</au><au>Takahashi, Keita</au><au>Toihata, Tasuku</au><au>Takemura, Ryo</au><au>Mayanagi, Shuhei</au><au>Hirata, Kenro</au><au>Irino, Tomoyuki</au><au>Hamamoto, Yasuo</au><au>Takeuchi, Hiroya</au><au>Watanabe, Masayuki</au><au>Kitagawa, Yuko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma</atitle><jtitle>Annals of surgery</jtitle><date>2022-08-01</date><risdate>2022</risdate><volume>276</volume><issue>2</issue><spage>298</spage><epage>304</epage><pages>298-304</pages><issn>0003-4932</issn><eissn>1528-1140</eissn><abstract>OBJECTIVE:This study aimed to elucidate the residual disease distribution and recurrence patterns in patients with ESCC responding to NAC. SUMMARY BACKGROUND DATA:To appropriately plan a prospective trial for the organ preservation approach which includes additional chemoradiotherapy in patients who responded to NAC, the distribution of residual disease needs to be elucidated. Given that the residual tumor is located in the regional field, chemoradiotherapy can be safely added to eliminate the residual disease. METHODS:Overall, 483 patients with resectable ESCC who received NAC followed by transthoracic esophagectomy at 2 high-volume centers were reviewed. The recurrence-free survival, overall survival (OS), and residual and recurrent tumor patterns were compared among the pathological responses. RESULTS:Compared with nonpathological responders, pathological responders exhibited significantly longer recurrence-free survival [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.25 (P &lt; 0.001) /0.17 (P &lt; 0.001) /0.16 (P = 0.003)] and OS [hazard ratio of Grade 1b/2/3 compared with Grade 0; 0.26 (P &lt; 0.001) /0.12 (P &lt; 0.001) /0.11 (P = 0.003)]. In terms of the distribution of recurrence, the percentages of solitary recurrence in the regional field out of all recurrence was significantly higher in patients with Grade 1b (60%) / 2 (67%) / 3 (67%) whereas less than 25% in Grade 0 or 1a. CONCLUSIONS:It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.</abstract><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><doi>10.1097/SLA.0000000000004436</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4932
ispartof Annals of surgery, 2022-08, Vol.276 (2), p.298-304
issn 0003-4932
1528-1140
language eng
recordid cdi_proquest_miscellaneous_2452498126
source PubMed Central; Journals@Ovid Complete
title Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T09%3A46%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distribution%20of%20Residual%20Disease%20and%20Recurrence%20Patterns%20in%20Pathological%20Responders%20After%20Neoadjuvant%20Chemotherapy%20for%20Esophageal%20Squamous%20Cell%20Carcinoma&rft.jtitle=Annals%20of%20surgery&rft.au=Matsuda,%20Satoru&rft.date=2022-08-01&rft.volume=276&rft.issue=2&rft.spage=298&rft.epage=304&rft.pages=298-304&rft.issn=0003-4932&rft.eissn=1528-1140&rft_id=info:doi/10.1097/SLA.0000000000004436&rft_dat=%3Cproquest_cross%3E2452498126%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2452498126&rft_id=info:pmid/&rfr_iscdi=true